CCM
Concord Medical Services Holdings Limited
There isn't enough reported data to score CCM yet.
NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
CCM Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Weak |
CCM's profitability and balance sheet are currently under pressure. There isn't enough data to rate its revenue and cash flow.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
CCM PE Valuation
CCM has no meaningful PE right now: it lost money over the past year.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
CCM Forward outlook
There aren't enough analyst estimates for CCM to show an outlook.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
CCM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2025 | -$0.11 | +$0.24 |
| Q4 2024 | -$0.35 | +$3.06 |
| Q4 2023 | -$3.41 | +$2.20 |
| Q4 2020 | -$7.67 | -$1.31 |
| Q4 2019 | -$6.36 | -$2.22 |
| Q4 2018 | -$4.14 | -$0.85 |
| Q4 2017 | -$3.29 | -$0.29 |
| Q4 2016 | -$3.00 | -$2.13 |
CCM is still losing money, but far less than before: $0.11 per share over the past year, against $7.67 at its worst in late 2020.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over CCM in the latest year-over-year earnings comparison.
CCM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2025 | $69.1M | +20% |
| Q4 2024 | $57.6M | -29% |
| Q4 2023 | $80.6M | +14% |
| Q4 2022 | $70.8M | -2.8% |
| Q4 2021 | $72.9M | +118% |
| Q4 2020 | $33.5M | +12% |
| Q4 2019 | $29.8M | +3.9% |
| Q4 2018 | $28.6M | -42% |
CCM's revenue is growing: $69M last quarter, down 5.2% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2025 | -57% | +38 points |
| Q4 2024 | -139% | +3.1 points |
| Q4 2023 | -86% | +134 points |
| Q4 2022 | -111% | +46 points |
| Q4 2021 | -94% | -30 points |
| Q4 2020 | -142% | -105 points |
| Q4 2019 | -220% | -220 points |
| Q4 2018 | -157% | -187 points |
CCM's operating margin was −57% last quarter, up 38 points from the same quarter a year ago.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over CCM in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO's operating margin was 34% last quarter, down 9 points from the same quarter a year ago, near the bottom of its range since 2019.
CCM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2025 | -$38.7M | +$43.6M |
| Q4 2024 | -$82.3M | -$23.9M |
| Q4 2023 | -$58.4M | +$7.5M |
| Q4 2022 | -$66M | +$29.8M |
| Q4 2021 | -$95.8M | -$36.1M |
| Q4 2020 | -$59.7M | +$4.5M |
| Q4 2019 | -$64.2M | -$33.6M |
| Q4 2018 | -$30.6M | -$21M |
CCM has burned cash in most quarters: −$245M over the past year, against −$250M the year before.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO still generates free cash flow, though less than at its 2026 peak: $7.3B over the past year.
CCM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -- |
| 1 year | +900% | +118M shares |
| 3 years | +733% | +115M shares |
CCM has 131M diluted shares, up 900% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2018 | — |
| Q4 2017 | — |
| Q4 2016 | $4.6M |
| Q4 2015 | $3M |
| Q4 2013 | $902,679 |
| Q4 2012 | $6.5M |
| Q4 2011 | $1M |
| Q4 2009 | — |
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over CCM on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
CCM Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2015 | 4.7x | High |
| Q4 2014 | 1.1x | Healthy |
| Q4 2013 | 2.2x | Moderate |
| Q4 2012 | 2.3x | Moderate |
CCM's net debt is about 4.7 years of its operating earnings (EBITDA).
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
CCM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.7 | Neutral |
| Stochastic | 28.6 | Neutral |
CCM's weekly RSI is 44 (neutral) and its Stochastic is 29 (neutral).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
CCM PE vs Healthcare Sector
CCM has no meaningful PE right now: it lost money over the past year.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
CCM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.65 | 2.7% below |
| 20 week MA | $4.17 | 15% below |
| 50 week MA | $4.24 | 16% below |
| 100 week MA | $4.79 | 26% below |
| 200 week MA | $7.27 | 51% below |
CCM is in a downtrend: it's below all five of its weekly moving averages, and 51% below its 200-week average.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has the edge over CCM on trend strength, trading above more of its moving averages.
CCM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $27.3 | $29.1 | +6.6% |
| 2021 | $29.1 | $20.5 | -30% |
| 2022 | $20.5 | $16.6 | -19% |
| 2023 | $16.6 | $11.0 | -34% |
| 2024 | $11.0 | $5.02 | -54% |
| 2025 | $5.02 | $3.76 | -25% |
| 2026 YTD | $3.76 | $3.55 | -5.6% |
CCM has the edge over NVO on returns for 2026, with the stronger performance.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.